#1 Clinical Trials Search in Europe

Eculizumab

Eculizumab, also known by its brand name Soliris, is a monoclonal antibody medication that has been the subject of numerous clinical trials for various medical conditions. This article explores the use of eculizumab in clinical trials for conditions such as kidney transplantation, neuromyelitis optica spectrum disorder (NMOSD), generalized myasthenia gravis (gMG), and others. We’ll examine the drug’s potential benefits, safety profile, and effectiveness across different patient populations.

Table of Contents

What is Eculizumab?

Eculizumab, also known by its brand name Soliris[1], is a specialized medication used to treat several rare but serious medical conditions. It belongs to a class of drugs called monoclonal antibodies, which are laboratory-created proteins designed to target specific substances in the body[2].

How Eculizumab Works

Eculizumab works by targeting and blocking a specific part of the body’s immune system called the complement system. Specifically, it binds to and inhibits a protein called C5, which is involved in the final stages of the complement cascade. By doing this, Eculizumab prevents the formation of the membrane attack complex (MAC), which can damage cells in certain diseases[1].

In simpler terms, Eculizumab acts like a shield, protecting certain cells in your body from being attacked by your own immune system in diseases where this process goes awry.

Conditions Treated with Eculizumab

Eculizumab is used to treat several rare but serious conditions, including:

  • Atypical Hemolytic Uremic Syndrome (aHUS): A rare condition that causes abnormal blood clots to form in small blood vessels throughout the body, leading to kidney damage[2].
  • Neuromyelitis Optica Spectrum Disorder (NMOSD): A rare autoimmune disease that affects the optic nerves and spinal cord, causing inflammation and potential vision loss or paralysis[3].
  • Membranoproliferative Glomerulonephritis (MPGN): A kidney disease that causes inflammation and changes in kidney function[1].
  • Guillain-Barré Syndrome (GBS): A rare disorder where the body’s immune system attacks the nerves, causing muscle weakness and sometimes paralysis[4].
  • Paroxysmal Nocturnal Hemoglobinuria (PNH): A rare blood disorder that causes red blood cells to break down faster than they should[5].

How Eculizumab is Administered

Eculizumab is typically given as an intravenous (IV) infusion, meaning it’s administered directly into your bloodstream through a vein. The dosage and frequency of administration can vary depending on the specific condition being treated and the patient’s body weight[1][3].

For example, in some studies, the dosing regimen for adults might look like this:

  • Initial phase: 900 mg weekly for 4 weeks
  • Maintenance phase: 1200 mg at week 5, then 1200 mg every 2 weeks thereafter

However, the exact dosing schedule can vary and will be determined by your healthcare provider based on your specific needs and condition[1].

Efficacy of Eculizumab

The effectiveness of Eculizumab has been studied in various clinical trials for different conditions. Here are some key findings:

  • In patients with NMOSD, Eculizumab has shown promise in reducing the frequency of relapses (flare-ups of the disease)[3].
  • For patients with aHUS, Eculizumab has demonstrated effectiveness in improving kidney function and reducing the need for dialysis[2].
  • In studies of patients with MPGN, Eculizumab has shown potential in reducing proteinuria (excess protein in urine, a sign of kidney damage)[1].
  • Research in GBS patients suggests that Eculizumab may help improve muscle strength and reduce the need for mechanical ventilation[4].

Safety and Side Effects

Like all medications, Eculizumab can cause side effects. Some of the potential side effects and safety considerations include:

  • Increased risk of certain types of infections, particularly meningococcal infections. Patients are typically vaccinated against these infections before starting treatment[6].
  • Common side effects may include headache, nausea, and upper respiratory tract infections[2].
  • In some studies, researchers closely monitor for adverse events, changes in vital signs, and abnormalities in laboratory tests[3].

It’s important to discuss potential risks and side effects with your healthcare provider before starting treatment with Eculizumab.

Ongoing Research and Future Applications

Researchers continue to study Eculizumab for various conditions. Some areas of ongoing research include:

  • Use in kidney transplantation to prevent antibody-mediated rejection[7].
  • Potential application in treating severe COVID-19 infections[8].
  • Investigating its use in pediatric patients with conditions like NMOSD[3].

These ongoing studies may lead to new applications for Eculizumab in the future, potentially benefiting more patients with rare and serious conditions.

Condition Key Findings Dosing Regimen Primary Outcomes
Kidney Transplantation Potential prevention of antibody-mediated rejection in ABO-incompatible transplants Single dose of 900 mg or 600 mg before transplant surgery Incidence of AMR within 6 months after transplantation
NMOSD Reduction in annualized relapse rate and disability progression Weight-based dosing every 2 weeks Change in annualized relapse rate and time to first relapse
Generalized Myasthenia Gravis Improvement in daily living activities and quality of life Induction and maintenance doses over 26 weeks Change in MG-ADL total score from baseline at Week 26
Dense Deposit Disease Potential improvement in kidney function and histological parameters 900 mg weekly for 4 weeks, then 1200 mg every 2 weeks for 1 year Change in proteinuria and serum creatinine over treatment period
COVID-19 Possible reduction in need for intubation and improvement in organ failure 1200 mg on Days 1, 4, 8, then 900-1200 mg on subsequent days Survival without needs of intubation at day 14 and change in organ failure at day 3

FAQ

  • What is eculizumab and how does it work? Eculizumab is a monoclonal antibody that targets and blocks the C5 protein in the complement system, a part of the immune system. By inhibiting C5, eculizumab prevents the formation of the membrane attack complex, which can damage cells and tissues in certain diseases.
  • In which conditions is eculizumab being studied? Eculizumab is being studied in various conditions, including kidney transplantation, neuromyelitis optica spectrum disorder (NMOSD), generalized myasthenia gravis (gMG), dense deposit disease, and COVID-19.
  • How is eculizumab administered in clinical trials? Eculizumab is typically administered intravenously (IV). The dosing regimen varies depending on the condition being treated and the specific trial protocol. For example, in some trials, it's given weekly for a few weeks, followed by bi-weekly maintenance doses.
  • What are some potential benefits of eculizumab in clinical trials? Potential benefits observed in clinical trials include prevention of antibody-mediated rejection in kidney transplants, reduction in relapses for NMOSD patients, improvement in daily living activities for gMG patients, and possible benefits in treating COVID-19 pneumonia.
  • Are there any safety concerns with eculizumab? As with any medication, there are potential side effects and safety concerns. Clinical trials monitor for adverse events, infections, and the development of anti-drug antibodies. Patients receiving eculizumab may also need to be vaccinated against certain infections, such as meningococcal disease, before starting treatment.

Ongoing Clinical Trials on Eculizumab

  • Study of Eculizumab in Adults with Hypertensive Emergency-Related Hemolytic Uremic Syndrome Requiring Dialysis or with Severe Kidney Problems

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study of KYV-101 Therapy for Patients with Refractory Generalized Myasthenia Gravis

    Recruiting

    4 1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany

  • Study on Gene Therapy with AAV9.LAMP2B for Male Patients with Danon Disease

    Recruiting

    2 1 1 1
    Investigated drugs:
    Germany Italy

  • Study on the Safety and Effects of UX701 Gene Therapy for Adults with Wilson Disease

    Recruiting

    2 1 1 1
    Investigated drugs:
    Denmark France Germany Italy Portugal Spain

  • Study of Microdystrophin (GNT0004) Gene Therapy for Duchenne Muscular Dystrophy in Boys Who Can Walk

    Recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France Spain

  • Study on the Safety of LY3884961 for Patients with Type 1 Gaucher Disease

    Not yet recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany Spain

  • Study on the Safety and Effectiveness of Pozelimab and Cemdisiran for Adults with Paroxysmal Nocturnal Hemoglobinuria Not Recently Treated with Complement Inhibitors

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Greece Hungary Italy Poland Romania Spain

  • Study Comparing Crovalimab and Eculizumab for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently on Complement Inhibitors

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Czechia Estonia France Germany Greece +7

  • Study on the Effectiveness and Safety of Crovalimab vs. Eculizumab for Adults and Adolescents with Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Treated with Complement Inhibitors

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Lithuania The Netherlands Poland Portugal +3

  • Study on the Long-term Safety and Effectiveness of Danicopan with Ravulizumab or Eculizumab for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

    Not recruiting

    3 1 1 1
    Investigated drugs:
    Czechia France Greece Italy Poland Spain

Glossary

  • Eculizumab: A monoclonal antibody medication that inhibits the complement system by binding to the C5 protein, preventing its cleavage and the formation of the membrane attack complex.
  • Complement system: A part of the immune system that enhances the ability of antibodies and phagocytic cells to clear microbes and damaged cells, promote inflammation, and attack the pathogen's cell membrane.
  • Neuromyelitis optica spectrum disorder (NMOSD): A rare autoimmune disease of the central nervous system that primarily affects the optic nerves and spinal cord, causing inflammation and damage to these areas.
  • Generalized myasthenia gravis (gMG): An autoimmune neuromuscular disorder characterized by weakness and rapid fatigue of voluntary muscles, affecting multiple muscle groups throughout the body.
  • Antibody-mediated rejection (AMR): A type of transplant rejection where the recipient's immune system produces antibodies that attack the transplanted organ, potentially leading to organ failure.
  • Annualized relapse rate (ARR): A measure used in clinical trials to assess the frequency of disease relapses or exacerbations over a year.
  • Expanded Disability Status Scale (EDSS): A method of quantifying disability in multiple sclerosis and monitoring changes in the level of disability over time.
  • Pharmacokinetics (PK): The study of how a drug is absorbed, distributed, metabolized, and excreted by the body over time.
  • Pharmacodynamics (PD): The study of the biochemical and physiological effects of drugs on the body, including their mechanisms of action and the relationship between drug concentration and effect.
  • Anti-drug antibodies (ADA): Antibodies produced by the immune system in response to a therapeutic drug, which can potentially reduce the drug's effectiveness or cause adverse reactions.

References

  1. https://clinicaltrials.gov/study/NCT02093533
  2. https://clinicaltrials.gov/study/NCT01757431
  3. https://clinicaltrials.gov/study/NCT04155424
  4. https://clinicaltrials.gov/study/NCT02493725
  5. https://clinicaltrials.gov/study/NCT02113891
  6. https://clinicaltrials.gov/study/NCT01221181
  7. https://clinicaltrials.gov/study/NCT06453135
  8. https://clinicaltrials.gov/study/NCT04346797